TKNO Alpha Teknova, Inc.

FY2025 10-K
Filed: Mar 2, 2026
Health Care
In Vitro & In Vivo Diagnostic SubstancesSEC EDGAR

Alpha Teknova, Inc. (TKNO) filed its fiscal year 2025 10-K annual report with the SEC on Mar 2, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2025 10-K

Business Overview

  • Core business model: Custom manufacturing of critical reagents for life sciences, supporting research to commercialization stages
  • New emphasis on scaling operations with investment in a new warehouse and distribution facility to improve capacity and efficiency
+3 more insights

Risk Factors

  • Regulatory risk: compliance with Second Amended and Restated Credit Agreement net revenue covenant of $39.0M for 2025, minimum cash requirement $8.0M
  • Macroeconomic exposure: 94.4% of revenue from U.S. customers, limited international diversification with only $2.3M (5.6%) sales outside U.S. in 2025
+3 more insights

Financial Summary
XBRL

Revenue

$41M

Net Income

-$17M

Gross Margin

33.2%

Operating Margin

-41.9%

Net Margin

-42.6%

ROE

-25.1%

Total Assets

$104M

EPS (Diluted)

$-0.32

Operating Cash Flow

-$9M

Source: XBRL data from Alpha Teknova, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.

Get deeper insights on Alpha Teknova, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available